Closer Surveillance for Asymptomatic Aortic Regurgitation, Given the Valve's Cause
A single patient whose aortic regurgitation hasn't crossed any guideline threshold yet, where one detail about its underlying cause changes how closely it should be watched.
J.O., a 45-year-old man, has taught high school physics for nineteen years, the kind of job where he says he's grown used to being the calm, methodical presence in a room — which made the phone call about his echocardiogram results feel unusually disorienting, arriving as it did after what he'd assumed was a routine workup for an incidental murmur.
The echocardiogram showed severe aortic regurgitation, discovered incidentally rather than through any symptom he'd noticed — no breathlessness, no chest discomfort, no reduced exercise tolerance. His left ventricular end-diastolic diameter measures 55mm, within the normal upper range and well short of the 65mm that would prompt intervention; his end-systolic diameter is likewise below the 50mm that carries more weight than the diastolic figure, and his ejection fraction is 60%, above the 55% trigger. The regurgitation traces back to a bicuspid aortic valve, identified on the same study — a congenital finding, not something that developed recently, though this is the first time it's been formally characterized. His ascending aorta measures 38mm on the same study, dilated but well below any surgical threshold — an assessment that is mandatory rather than optional once a valve is known to be bicuspid, since aneurysm accompanies the valve in a substantial minority of cases. His blood pressure is well controlled without medication, and there is no family history of aortic disease.
Standard guidance for asymptomatic severe AR relies on LV size and function crossing defined thresholds before intervention is considered, and by that standard he isn't close. What the standard surveillance interval doesn't fully account for is that close monitoring in the first two to three years after diagnosis is specifically advised for bicuspid-valve disease, and there's no prior echocardiogram to establish how fast his own disease is actually moving — today's measurements are a single snapshot, not yet a trend.
How closely to watch a valve without a track record yet
By the numbers alone, this is standard surveillance — he hasn't crossed any threshold for intervention, and the guideline-directed interval for asymptomatic severe AR with normal LV size is annual imaging. I don't see a reason to deviate from that protocol based on today's single set of measurements.
I'd deviate from the standard interval specifically because of the bicuspid etiology. That's not incidental — the first years after a bicuspid valve is identified are exactly when closer monitoring is advised, and we have no prior echocardiogram to know whether he's been stable for years or is early in a faster trajectory. I'd want imaging at six months rather than waiting the full year, purely to establish his own rate of change before defaulting to the standard schedule.
That seems like the right call to me — closer surveillance costs him very little and directly addresses the actual uncertainty here, which isn't whether he needs intervention today but how quickly this might be moving. Once we have two data points instead of one, the standard interval becomes a much more informed decision than it is right now.
Surveillance interval shortened to six months rather than the standard annual schedule, specifically because of his bicuspid-valve etiology and the absence of any prior imaging to establish his personal disease trajectory. No change to medical therapy or intervention threshold.
The interval can reasonably extend back toward the standard annual schedule, now with an actual trend established.
The closer interval continues, and the intervention-threshold conversation moves closer than the single snapshot today would have suggested.
The cardiologist's instinct to follow the standard protocol wasn't wrong on its own terms — he genuinely hasn't crossed any threshold — the surgeon's point was narrower: that the protocol assumes a trend already exists to follow, which for this specific patient, on this specific valve, hasn't actually been established yet.